SeenewsSeenews
Search
Seenews
AlertsSeenewsSeenews
Searchclose
TOPICS
arrow
COUNTRIES
arrow
INDUSTRY
arrow
Economy
arrow
Browse Economy
Mix and match your focus countries with our advanced search
Investments
arrow
Browse Investments
Mix and match your focus countries with our advanced search
Deals
arrow
Browse Deals
Mix and match your focus countries with our advanced search
Tech
arrow
Browse Tech
Mix and match your focus countries with our advanced search
Green
arrow
Browse Green
Mix and match your focus countries with our advanced search
0/5
You have 5 free articles left this month
You have 0/5 free articles
Sign up to get 5 more free articles this month
SIGN UP
arrow
LOGIN
arrow

STOCKWATCH - Erste adds Slovenia's Krka to CEE/Turkey top 10 stock picks for Q4

Oct 1, 2012, 1:01:40 PMArticle by Kire Nedelkovski
share
October 1 (SeeNews) - Austria's Erste Group Research said on Monday it has added Slovenia's Krka [LJE:KRKG] to its top 10 equity picks in Central and Eastern Europe (CEE) and Turkey for the fourth quarter of 2012, recommending a 'buy' on stock of the blue-chip drug maker.

STOCKWATCH - Erste adds Slovenia's Krka to CEE/Turkey top 10 stock picks for Q4

The research outfit's 10 top equity picks represent its best investment short- to mid-term ideas.

Delivering a first-half net profit of 90.1 million euro ($116.1 million) on sales of 565.3 million euro (up 6.9% year-on-year), Krka reassured investors that it is well on track to meet or even surpass its 2012 guidance of sales growth of 6.0% on the year to 1.1 billion euro and net profit of 170 million euro, Erste Group Research said in a statement.

"Although the pricing pressures in the CEE region continue to hurt the company, this is to be offset by dynamically growing Russia/CIS. Krka’s top line growth is thus set to remain solid. The own Russian manufacturing base (with further investment worth 135 million euro planned to be finished next year) and an excellent sales network bode well for retaining Krka’s status as the second largest among the CEE-based Russian players," the statement said.

The Erste analysts said Krka’s strong innovative edge (high share of new products in its sales mix) should provide an antidote to pricing pressures and help the company keep its profitability margins above its peers’. "Krka’s high-quality R&D pipeline, rich in generics coming off-patent, is fueling its success in Western markets."

“Should the market conditions improve, management is committed to pursuing next steps in the Warsaw listing, i.e. offering treasury shares to investors, including Polish pension funds,” the statement said.

“Historically, the stock used to be traded at a premium to its CEE-based pharma peers. Not only has this premium evaporated, but the stock price has dropped to levels that fail to adequately reflect the company’s competitive advantages [..]. With our DCF-based target price suggesting some 40% upside potential, we think that our Buy call for Krka is fully justified,” it added. Erste's target price for the stock is 69.5 euro.

Krka was trading flat at 49.8 euro by 0935 GMT on the Ljubljana bourse on Monday.

($ = 0.7762 euro)

Your complete guide to the emerging economies of Southeast Europe. From latest news to bespoke research – the big picture at the tip of your fingers.